Your browser version may not work well with NCBI's Web applications. More information here...
1: Antimicrob Agents Chemother. 2000 Nov;44(11):3180-3.Click here to read Click here to read Links

Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections.

Odds FC, Oris M, Van Dorsselaer P, Van Gerven F.

Department of Molecular and Cell Biology, University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, Scotland, United Kingdom. f.odds@abdn.ac.uk

An intravenous (i.v.) formulation of itraconazole was evaluated in disseminated fungal infection models in guinea pigs. In acute disseminated Candida albicans and Aspergillus fumigatus infections, treatment at 5 mg/kg of body weight twice a day (b.i.d.) significantly prolonged survival. In these models and in animals with chronic disseminated cryptococcosis, itraconazole given i.v. at 2.5 and 5 mg/kg b.i.d. greatly reduced the proportions of organs with culture-detectable fungal burdens. The efficacy of i.v. itraconazole in these animal models justifies its further investigation for the treatment of life-threatening mycoses in humans.

PMID: 11036047 [PubMed - indexed for MEDLINE]

PMCID: PMC101627

Patient Drug Information

  • Itraconazole (Sporanox® )

    Itraconazole capsules are used to treat fungal infections that begin in the lungsand can spread through the body. Itraconazole capsules are also used to treat fungal infections of the fingernails and/or toenails. Itracon...

  • Source: AHFS Consumer Medication Information